Non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)‐mutated who progressed on EGFR tyrosine‐kinase inhibitor (EGFR‐TKI) therapy have limited therapeutic options. This evidence concerns the gene EGFR and lung cancer.